January 2018

Arko Dasgupta, PhD

Arko Dasgupta, PhD Fred Hutchinson Cancer Research Center Breast cancer is a major killer in the United States and metastases are the primary cause of breast cancer-related deaths. Approximately 30% of breast cancer patients will develop metastases during their lifetime. Few prognostic factors predict metastases as well as the presence of dormant disseminated tumor cells […]

Arko Dasgupta, PhD Read More »

Sheng Sun, PhD

Sheng Sun, PhD Massachusetts General Hospital Cancer Center The majority of breast cancers express hormone receptors, and therapies that antagonize hormonal signaling via these receptors are the most effective treatments for hormone receptor-positive metastatic breast cancer (HR+ MBC). Unfortunately, for the vast majority of patients with hormonal therapy-refractory MBC, the mechanisms of resistance remain poorly

Sheng Sun, PhD Read More »

Adrienne Gropper Waks, MD

Adrienne Gropper Waks, MD Dana-Farber Cancer Institute Following many important advances in treating HER2-positive breast cancer over the past two decades, a large majority of patients with non-metastatic HER2-positive tumors are cured with today’s treatments. For this majority of patients who do well in the long-term, we must begin to identify ways to cure HER2-positive breast

Adrienne Gropper Waks, MD Read More »

Scroll to Top
Skip to content